MENLO PARK, Calif.,
May 24, 2018 /PRNewswire/
-- BioPharmX Corporation (NYSE American: BPMX), a specialty
pharmaceutical company developing products for the dermatology
market, will present research showing that the topical delivery of
minocycline in a gel formulation may offer a more targeted path to
treating acne and rosacea than oral formulations that could make it
the preferred treatment option for patients with those
indications.
The poster presentation, "Early Data from BPX-04 Topical
Minocycline Gel for Rosacea Supported by Data From BPX-01 Topical
Minocycline Gel for Acne: A Review," will be shared at the Congress
of Clinical Dermatology, May 25-28,
in Miramar Beach, Fla. The
presentation concludes that, because topical minocycline
formulations may avoid systemic side effects commonly associated
with oral formulations of minocycline, as well as the cutaneous
irritation common in other topical treatments, dermatologists may
prefer these formulations for treatment of acne and rosacea.
"Dermatologists favor medicines that make it easy for patients
to follow treatment programs. By reducing the risk of adverse
effects and antibiotic resistance, the topical BioPharmX
formulations may fulfill needs currently being addressed by a
combination of oral antibiotics and topical therapies," said Hilary
Baldwin, Medical Director of the Acne Treatment & Research
Center in Morristown, NJ, and
co-chair of the BioPharmX Medical Advisory Board. "The fact that
this unique hydrophilic delivery system effectively delivers
minocycline in a targeted way without the adverse effects
associated with either oral antibiotics or many alternative topical
products holds exciting promise."
Oral minocycline has been widely used since the 1970s, but the
pharmaceutical industry has not previously been able to develop a
stable, topical formulation of fully solubilized minocycline, which
produces less resistance than other tetracycline-class antibiotics
commonly used for these diseases. BioPharmX is the first company to
develop a topical gel formulation of minocycline that reaches not
only the epidermis where rosacea manifests itself, but also deeper
into the pilosebaseous unit, where acne develops. By applying
minocycline topically, a patient may reduce the systemic uptake of
minocycline and focus the drug's beneficial effects on the skin
where they are needed most.
Additional data from the studies on BPX-01 and BPX-04 will be
highlighted from the podium in the following presentations:
- What's New in Dermatologic Therapy, James Q. Del Rosso, DO May 26, 9:15-10:00am
- Management of Rosacea: From Benchtop to Treatment,
James Q. Del Rosso, DO May 27, 10:40-11:10am
- Treating Acne in the 22nd Century, Hillary E. Baldwin, MD May 27, 11:10-11:40am
BioPharmX has successfully completed a phase 2b trial for BPX-01 and is preparing for phase 3
trials in acne. The company is currently conducting a
feasibility study for BPX-04 in rosacea and is preparing for a
phase 2 trial.
About BPX-01 and BPX-04
BPX-011 and BPX-041 are hydrophilic
(non-oil-based) topical gels with fully solubilized minocycline
that have been shown to penetrate the skin to deliver the
antibiotic to its target. Following positive results from its
previously announced phase 2b dose
range study of BPX-01 in acne, BioPharmX continues with phase 3
clinical study plans for BPX-01 for the treatment of inflammatory
lesions of acne.
About BioPharmX Corporation
BioPharmX Corporation (NYSE American: BPMX) is a Silicon
Valley-based specialty pharmaceutical company, which seeks to
provide products through proprietary platform technologies for
prescription, over-the-counter, and supplement applications in the
health and wellness markets, including dermatology and women's
health. To learn more about BioPharmX,
visit www.BioPharmX.com.
Forward-Looking Statements
The information in this press release contains forward-looking
statements and information within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which are subject to
the "safe harbor" created by those sections. Forward-looking
statements about the company's expectations, plans, intentions, and
strategies, include, but are not limited to, statements regarding
the ability of hydrophilic topical minocycline gels to become a
preferred treatment option for acne and rosacea patients, our
ability to prepare for and successfully execute the phase 3 trial
for BPX-01 and the phase 2 trial for BPX-04, the results of and the
size of such trials, the safety and medical effects of BPX-01 and
BPX-04, the effect BPX-01 and BPX-04 may have on the treatment of
acne and rosacea, the continued and consistent results in future
tests of BPX-01 and BPX-04, and absence of side effects of future
use of BPX-01 and BPX-04. These forward-looking statements may be
identified by words such as "plan," "expect," "anticipate,"
"believe," "intend," "should," "may" or similar
expressions.
These forward-looking statements involve risks and
uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause our results to differ
materially from those expressed or implied by such forward-looking
statements. The risks and uncertainties include those described in
the company's filings with the Securities and Exchange Commission,
including our annual report on Form 10-K for the fiscal year
ended Jan. 31, 2018 and our subsequent quarterly reports on
Form 10-Q. Given these risks and uncertainties, you are cautioned
not to place undue reliance on such forward-looking statements. The
forward-looking statements included in this news release are made
only as of the date hereof, and the company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as may be required under applicable securities
law.
1 Caution: BPX-01 and BPX-04 are new drugs limited by
U.S. law to investigational use.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biopharmx-studies-show-hydrophilic-topical-minocycline-gels-may-be-the-preferred-treatment-option-for-acne-rosacea-patients-300653057.html
SOURCE BioPharmX Corporation